CDK2 interactions
    1.
    发明授权
    CDK2 interactions 失效
    CDK2相互作用

    公开(公告)号:US5986055A

    公开(公告)日:1999-11-16

    申请号:US969106

    申请日:1997-11-13

    摘要: The present invention relates to complexes of the CDK2 protein with proteins identified as interacting with CDK2 by a modified yeast two hybrid assay system. The proteins identified to interact with CDK2 are cyclin H, cyclin I, ERH, and two gene products, hsReq*-1 and hsReq*-2, which are splice variants of the gene hsReq. Thus, the invention provides complexes of CDK2 and cyclin H, cyclin I, ERH, hsReq*-1, and hsReq*-2, and derivatives, fragments and analogs thereof. The invention also provides nucleic acids encoding the hsReq*-1 and hsReq*-2, and proteins and derivatives, fragments and analogs thereof. Methods of screening the complexes for efficacy in treating and/or preventing certain diseases and disorders, particularly cancer, atherosclerosis and neurodegenerative disease are also provided.

    摘要翻译: 本发明涉及CDK2蛋白与通过修饰的酵母双杂交测定系统鉴定为与CDK2相互作用的蛋白质的复合物。 鉴定为与CDK2相互作用的蛋白质是细胞周期蛋白H,细胞周期蛋白I,ERH和两个基因产物hsReq * -1和hsReq * -2,它们是hsReq基因的剪接变体。 因此,本发明提供了CDK2和细胞周期蛋白H,细胞周期蛋白I,ERH,hsReq * -1和hsReq * -2及其衍生物,片段和类似物的复合物。 本发明还提供编码hsReq * -1和hsReq * -2的核酸,以及蛋白质及其衍生物,片段和类似物。 还提供了筛选复合物治疗和/或预防某些疾病和病症,特别是癌症,动脉粥样硬化和神经变性疾病的功效的方法。